Parkinson disease (PD) is a progressive disorder characterized by dopaminergic
neurodegeneration in the brain. The development of parkinsonism is preceded by a long …

Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …

The diagnosis of Parkinson's disease (PD) occurs after pathogenesis is advanced and many
substantia nigra (SN) dopamine neurons have already died. Now that therapies to block this …

Parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the
midbrain. There are various imaging markers for Parkinson disease. Recent advances in …

The differential diagnosis of parkinsonian syndromes is considered one of the most
challenging in neurology and error rates in the clinical diagnosis can be high even at …

Parkinson's disease (PD) is currently clinically defined by a set of cardinal motor features
centred on the presence of bradykinesia and at least one additional motor symptom out of …

Parkinson's disease (PD) is a progressive neurodegenerative disorder in which the major
pathologic substrate is a loss of dopaminergic neurons from the substantia nigra. Our main …

Background Dorsolateral nigral hyperintensity on iron‐sensitive magnetic resonance
imaging (MRI) sequences seems to be a typical finding in Parkinson's disease (PD), but …

Parkinson's disease (PD) is a clinically heterogeneous chronic progressive neuro-
degenerative disease with loss of dopaminergic neurons in the nigrosome 1 (N1) territory of …

Abstract Neuroimaging using the 7-Tesla (7T) human magnetic resonance (MR) system is
rapidly gaining popularity after being approved for clinical use in the European Union and …